ArticleFrontiers in oncology2025
Imaging and pathological characteristics of hepatosplenic EBV-positive inflammatory follicular dendritic cell sarcoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma of the liver: clinical features, imaging findings and potential diagnostic clues.Abdominal radiology (New York) · 2026Article
- Epstein-Barr virusOncology letters · 2026Article
- A Case Report of follicular dendritic cell sarcoma.Frontiers in oncology · 2026Article
- Hepatic Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Diagnostic Imaging Challenge - A Focused Review and Case Report.Current medical imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study is to explore the CT and MRI characteristics of hepatosplenic Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (IFDCS) and to correlate these findings with pathological characteristics to enhance diagnostic understanding. Case description: A retrospective analysis was conducted on 16 patients with surgically confirmed hepatosplenic EBV-positive IFDCS, who underwent CT and MRI between January 2015 and May 2024. Clinical, pathological, and imaging data were evaluated. Results: Hepatosplenic EBV-positive IFDCS primarily occurred in middle-aged adults, with a greater prevalence in females. All cases presented as solitary, well-defined masses, either round or oval in shape. Calcification was noted in one case, while necrosis and cystic degeneration were observed in nine cases. Contrast-enhanced CT and MRI showed that 15 cases exhibited heterogeneous, mild to moderate persistent uneven enhancement of the tumor parenchyma, with most lesions appearing hypodense or hypointense in the delayed phase. The majority of cases showed a hypodense or hypointense capsule with delayed enhancement. Solid tumor components appeared hyperintense on diffusion-weighted imaging (DWI), with apparent diffusion coefficient values similar to those of the spleen. One case of hepatic EBV-positive IFDCS exhibited an atypical enhancement pattern characterized by rapid wash-in and slow wash-out. Conclusion: MRI proved superior in visualizing the tumor capsule and providing qualitative diagnostic information, yielding crucial information for clinical diagnosis and preoperative evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.